---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-241736"
form_type: "8-K"
ticker: "RVMD"
cik: "0001628171"
company_name: "Revolution Medicines, Inc."
filed_at: "2025-10-17T23:59:59+00:00"
generated_at: "2026-05-17T03:24:00.820556+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Revolution Medicines receives FDA national priority voucher for daraxonrasib

## Summary
- FDA granted a non-transferrable voucher under the Commissioner's National Priority Voucher pilot program.
- Voucher is for daraxonrasib, the company's RAS(ON) multi-selective inhibitor.
- Announcement made on October 16, 2025; no financial terms disclosed.

## SEC filing metadata
- accession: 0001193125-25-241736
- form_type: 8-K
- ticker: RVMD
- cik: 0001628171
- company_name: Revolution Medicines, Inc.
- filed_at: 2025-10-17T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628171/000119312525241736/0001193125-25-241736-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628171/000119312525241736/d32252d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-241736
- JSON: https://secwatch.observer/filing/0001193125-25-241736.json
- Plain text: https://secwatch.observer/filing/0001193125-25-241736.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.